Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bioxcel Therapeutics Inc.

1.37
+0.06004.58%
Post-market: 1.370.00000.00%19:59 EDT
Volume:109.47M
Turnover:187.90M
Market Cap:8.30M
PE:-0.11
High:2.07
Open:1.66
Low:1.33
Close:1.31
Loading ...

BioXcel Therapeutics Inc expected to post a loss of $1.63 a share - Earnings Preview

Reuters
·
01 Aug

BioXcel Therapeutics Inc - Topline Data Readout Anticipated This Month

THOMSON REUTERS
·
01 Aug

Mizuho Slashes Price Target on BioXcel Therapeutics to $2 From $16, Keeps Neutral Rating

MT Newswires Live
·
28 Jul

BRIEF-Bioxcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package In Support Of Potential Label Expansion For Igalmi

Reuters
·
21 Jul

Lucid reiterates Buy on BioXcel after patent application approval

TIPRANKS
·
15 Jul

BioXcel Therapeutics Announces Allowance of U.S. Patent Application for Igalmi Dosing Regimen in Treating Acute Agitation

Reuters
·
15 Jul

BUZZ-U.S. STOCKS ON THE MOVE-Energy stocks, Apple, Vertex

Reuters
·
02 Jul

BUZZ-U.S. STOCKS ON THE MOVE-NIP Group, Hyatt, BioXcel Therapeutics

Reuters
·
01 Jul

BRIEF-Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia

Reuters
·
01 Jul

BioXcel Therapeutics initiated with a Buy at Lucid Capital

TIPRANKS
·
25 Jun

BioXcel granted extension to regain compliance with Nasdaq listing requirement

TIPRANKS
·
27 May

BioXcel Therapeutics Inc expected to post a loss of $6.66 a share - Earnings Preview

Reuters
·
05 May

BRIEF-Bioxcel Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $8.1 Million From Time To Time Through Canaccord - SEC Filing

Reuters
·
04 Apr

Bank of America Securities Keeps Their Sell Rating on Bioxcel Therapeutics (BTAI)

TIPRANKS
·
28 Mar

BioXcel Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Mar

BioXcel Therapeutics Q4 2024 GAAP EPS $(3.57) Beats $(6.59) Estimate, Sales $366K Miss $706.667K Estimate

Benzinga
·
27 Mar

BRIEF-BioXcel Therapeutics Q4 Basic EPS USD -3.57 Vs. IBES Estimate USD -6.22

Reuters
·
27 Mar

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

GlobeNewswire
·
27 Mar

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight

Zacks
·
20 Mar

BioXcel Therapeutics Initiated at Buy by Rodman & Renshaw

Dow Jones
·
19 Mar